MedTrace Logo

Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium

NCT06424964 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-02-05

No results posted yet for this study

Summary

This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.

Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV

Secondary outcomes

• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis

Conditions

  • Human Immunodeficiency Virus

Sponsors & Collaborators

  • Belgian Research on AIDS and HIV Consortium

    lead OTHER

Principal Investigators

  • Stéphane De Wit, MD/PhD · Belgian Research on AIDS & HIV Consortium

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-13
Primary Completion
2025-05-31
Completion
2025-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06424964 on ClinicalTrials.gov